+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global CRISPR & Cas Genes Market Size, Share & Trends Analysis by Product & Service (Vector-based Cas, DNA-free Cas, Cell Line Engineering), Application, End Use, and Segment Forecasts 2020-2027

  • ID: 4076528
  • Report
  • May 2020
  • Region: Global
  • 212 Pages
  • Grand View Research

FEATURED COMPANIES

  • Addgene
  • Caribou Biosciences, Inc.
  • Crispr Therapeutics
  • Egenesis
  • Inscripta, Inc.
  • Merck Kgaa
CRISPR & Cas Genes Market Growth & Trends

The global clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) genes market size is expected to reach USD 4.88 billion by 2027, expanding at a CAGR of 16.6% from 2020 to 2027. Rise in the adoption of CRISPR technology in epigenetics, therapeutics, human germline editing, plant genome editing, and other fields of biotechnology is expected to drive the market.

Presence of a large number of service providers that provide knockout, knock-in, gene repression, gene activation, and other cell line engineering services propel the growth of cell line engineering services. In biomedical applications, genome engineering held the largest revenue share in 2019. Adoption of gene editing techniques for human- and non-human-based genomic engineering is one of the key factors that drive the segment.

The molecular scissor can facilitate the detection of viruses, allowing the development of cost-effective, robust, and rapid point-of-care diagnostics. It allows the detection of viruses at a level of molecular concentration that researchers rarely assess. Sherlock Bioscience estimated that a CRISPR-powered diagnostic test would be available in the future at a reasonable price. In recent times, the most important innovation has been the development of a test for COVID-19.

In March 2020, Mesa Biotech announced FDA authorization for its Accula device, a hand-held COVID-19 diagnostic test. Similarly, in April 2020, CSIR lab announced the development of a paper-strip test for Covid-19 that uses CRISPR-Cas9 to target and identifies the genomic sequences of the virus. Unlike the PCR tests, this test is available at a very low price, USD 6.59 (INR 1 = USD 0.013). Therefore, such initiatives are expected to encourage other players to leverage this crisis and launch novel products.

CRISPR & Cas Genes Market Report Highlights
  • The product segment is anticipated to dominate the market throughout the forecast period. This is attributed to the presence of enhanced individual products that can serve multiple purposes including genome engineering, specific genome cleavage using gRNAs, easy gene knockouts, along with reduced off-target cutting, and increased specificity
  • Cell line engineering services accounted for the largest market share in 2019. The development of this technology has simplified the genome engineering process to a large extent
  • In biomedical applications, genome engineering held the largest revenue share in 2019 as a result of an increase in the adoption of genome editing techniques for modifications in germline and therapeutics development
  • Recent advancements in CRISPR/Cas genome editing allow targeted modification in crops, thereby promising crop improvement and revenue generation in the market
  • A significant number of research studies carried out to develop disease-specific novel therapies and the presence of a huge clinical pipeline that integrates the application of this gene-editing technology are expected to boost revenue generation for the biotechnology and pharmaceutical companies segment
  • Asia Pacific is anticipated to witness the fastest growth over the forecast period. China holds a significant position in the CRISPR market and is increasingly exploring genome-editing for the development of medicines. The country has launched several CRISPER-based clinical trials, especially for cancer treatment.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Addgene
  • Caribou Biosciences, Inc.
  • Crispr Therapeutics
  • Egenesis
  • Inscripta, Inc.
  • Merck Kgaa
Chapter 1 Research Methodology
1.1 Information Procurement
1.2 Information Or Data Analysis
1.3 Market Model
1.3.1 Parent Market Study
1.3.2 Crispr And Cas Genes Market Study
1.3.2.1 Market Study, By Product & Service
1.3.2.2 Market Study, By Application
1.3.2.3 Market Study, By End - Use
1.3.2.4 Market Study, By Region
1.4 Objectives
1.4.1 Objective 1:
1.4.2 Objective 2:

Chapter 2 Executive Summary
2.1 Market Snapshot, 2019 (USD Million)

Chapter 3 Crispr And Cas Genes Market Variables, Trends & Scope
3.1 Market Trends & Outlook
3.2 Market Segmentation & Scope
3.3 Market Lineage Outlook
3.3.1 Parent Market Outlook
3.3.2 Related/Ancillary Market Outlook
3.4 Crispr And Cas Genes: Patent Landscape
3.4.1 By End - Use Settings
3.4.2 By Variants Of Crispr Enzymes
3.5 Penetration And Growth Prospect Mapping, By Biomedical Applications, 2019
3.6 Potential Threat Analysis To Crispr Technology
3.6.1 Variations In The Crispr System
3.7 Investors Perspective Analysis
3.8 User Perspective Analysis
3.9 Technology Mapping In Crispr Genome Editing Workflow
3.10 Developments And Innovations For Analysis Of Off - Target Effects
3.11 Crispr Technologies: Clinical Penetration
3.11.1 Human Therapeutics
3.11.2 Diagnostics
3.11.3 Microbiome Research And Drug Resistance
3.11.4 Animal Disease Models

Chapter 4 Industry Outlook
4.1 Market Dynamics
4.1.1 Market Driver Analysis
4.1.1.1 Rising Adoption In Diverse Fields Of Biotechnology
4.1.1.1.1 Epigenetics
4.1.1.1.2 Medicine
4.1.1.1.3 Human Germline Editing
4.1.1.1.4 Tool For Qualitative And Quantitative Plant Genome Editing
4.1.1.2 Technological Advancements In Crispr
4.1.1.3 Introduction Of Anti - Crispr Protein
4.1.1.4 Ongoing Competition For Crispr Commercialization
4.1.2 Market Restraint Analysis
4.1.2.1 Off - Target Effects Of Crispr Technology
4.1.2.2 Intellectual Property Disputes Pertaining To Cas
4.1.2.3 Ethical Concerns And Implications With Respect To Human Genome Editing
4.1.3 Market Opportunity Analysis
4.1.3.1 Expanding Gene & Cell Therapy Area
4.1.3.2 Government Fund In Genomic R&D
4.1.4 Market Challenge Analysis
4.1.4.1 Risks Pertaining To The Usage Of Genetically Modified Food
4.2 Policy Making & Regulation For Genetic Modification Using Crispr
4.3 Porter’s Five Forces Analysis
4.3.1 Threat Of New Entrants: Moderate
4.3.2 Competitive Rivalry: High
4.3.3 Threat Of Substitutes: Moderate
4.3.4 Bargaining Power Of Suppliers: Low
4.3.5 Bargaining Power Of Buyers: Moderate
4.4 SWOT Analysis, By Factor (Political & Legal, Economic, And Technological)
4.4.1 Political & Legal
4.4.2 Economic
4.4.3 Technological

Chapter 5 Competitive Landscape
5.1 Companies (Diagnostic & Drug Developers) Leveraging Gene Editing Technologies
5.2 Major Deals & Strategic Alliances Analysis
5.3 Market Entry Strategies
5.3.1 Crispr Therapeutics: Business Translation
5.3.2 Crispr Gene Editing Companies’ Toolboxes
5.4 Crispr And Cas Genes Market: Pipeline Analysis
5.4.1 Editas Medicine
5.4.2 Intellia Therapeutics, Inc.
5.4.3 Crispr Therapeutics
5.4.4 Caribou Biosciences, Inc.
5.4.5 Egenesis
5.4.6 Beam Therapeutics
5.4.7 Ksq Therapeutics
5.4.8 Cibus

Chapter 6 Product & Service Business Analysis
6.1 Crispr And Cas Genes Market: Product & Service Movement Analysis
6.2 By Product
6.2.1 Global Crispr And Cas Genes Products Market, 2016 - 2027 (USD Million)
6.2.2 Kits & Enzymes
6.2.3 Global Crispr And Cas Genes Kits And Enzymes Market, 2016 - 2027 (USD Million)
6.2.3.1 Vector - Based Cas9
6.2.3.1.1 Global Vector - Based Cas9 Market, 2016 - 2027 (USD Million)
6.2.3.2 Dna - Free Cas9
6.2.3.2.1 Global Dna - Free Cas9 Market, 2016 - 2027 (USD Million)
6.2.4 Libraries
6.2.4.1 Global Crispr And Cas Genes Libraries Market, 2016 - 2027 (USD Million)
6.2.5 Design Tools
6.2.5.1 Global Crispr And Cas Genes Design Tool Market, 2016 - 2027 (USD Million)
6.2.6 Antibodies
6.2.6.1 Global Crispr And Cas Genes Antibodies Market, 2016 - 2027 (USD Million)
6.2.7 Others
6.2.7.1 Global Crispr And Cas Genes Market For Other Products, 2016 - 2027 (USD Million)
6.3 By Service
6.3.1 Global Crispr And Cas Genes Service Market, 2016 - 2027 (USD Million)
6.3.2 Cell Line Engineering
6.3.2.1 Global Cell Engineering Services Market, 2016 - 2027 (USD Million)
6.3.3 Grna Design
6.3.3.1 Global Grna Design Market, 2016 - 2027 (USD Million)
6.3.4 Microbial Gene Editing
6.3.4.1 Global Microbial Gene Editing Market, 2016 - 2027 (USD Million)
6.3.5 Dna Synthesis
6.3.5.1 Global Dna Synthesis Market, 2016 - 2027 (USD Million)

Chapter 7 Application Business Analysis
7.1 Crispr And Cas Genes Market: Application Movement Analysis
7.2 Biomedical
7.2.1 Global Crispr And Cas Genes Market For Biomedical, 2016 - 2027 (USD Million)
7.2.2 Genome Engineering
7.2.2.1 Global Crispr And Cas Genes Market For Genome Engineering, 2016 - 2027 (USD Million)
7.2.3 Disease Model Studies
7.2.3.1 Global Crispr And Cas Genes Market For Disease Model Studies, 2016 - 2027 (USD Million)
7.2.4 Functional Genomics
7.2.4.1 Global Crispr And Cas Genes Market For Functional Genomics, 2016 - 2027 (USD Million)
7.2.5 Epigenetics
7.2.5.1 Global Crispr And Cas Genes Market For Epigenetics, 2016 - 2027 (USD Million)
7.2.6 Others
7.2.6.1 Global Crispr And Cas Genes Market For Other Biomedical Applications, 2016 - 2027 (USD Million)
7.3 Agriculture
7.3.1 Global Crispr And Cas Genes Market For Agriculture, 2016 - 2027 (USD Million)

Chapter 8 End - Use Business Analysis
8.1 Crispr And Cas Genes Market: End - Use Movement Analysis
8.1.1 Biotechnology & Pharmaceutical Companies
8.1.1.1 Global Crispr And Cas Genes Market For Biotechnology & Pharmaceutical Companies, 2016 - 2027 (USD Million)
8.1.2 Academics & Government Research Institutes
8.1.2.1 Global Crispr And Cas Genes Market For Academics & Government Research Institutes, 2016 - 2027 (USD Million)
8.1.3 Contract Research Organizations (Cros)
8.1.3.1 Global Crispr And Cas Genes Market For Cros, 2016 - 2027 (USD Million)

Chapter 9 Regional Business Analysis
9.1 Crispr And Cas Genes Market: Regional Movement Analysis, 2019 And 2027
9.2 North America
9.2.1 North America Crispr And Cas Genes Market Estimates And Forecast, 2016 - 2027 (USD Million)
9.2.2 U.S.
9.2.2.1 U.S. Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
9.2.2.2 U.S. Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
9.2.2.3 U.S. Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)
9.2.3 Canada
9.2.3.1 Canada Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
9.2.3.2 Canada Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
9.2.3.3 Canada Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)
9.3 Europe
9.3.1 Europe Crispr And Cas Genes Market Estimates And Forecast, 2016 - 2027 (USD Million)
9.3.2 Germany
9.3.2.1 Germany Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
9.3.2.2 Germany Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
9.3.2.3 Germany Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)
9.3.3 U.K.
9.3.3.1 U.K. Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
9.3.3.2 U.K. Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
9.3.3.3 U.K. Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)
9.3.4 France
9.3.4.1 France Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
9.3.4.2 France Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
9.3.4.3 France Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)
9.3.5 Itlay
9.3.5.1 Italy Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
9.3.5.2 Italy Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
9.3.5.3 Italy Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)
9.3.6 Spain
9.3.6.1 Spain Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
9.3.6.2 Spain Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
9.3.6.3 Spain Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)
9.4 Asia Pacific
9.4.1 Asia Pacific Crispr And Cas Genes Market Estimates And Forecast, 2016 - 2027 (USD Million)
9.4.2 Japan
9.4.2.1 Japan Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
9.4.2.2 Japan Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
9.4.2.3 Japan Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)
9.4.3 China
9.4.3.1 China Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
9.4.3.2 China Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
9.4.3.3 China Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)
9.4.4 South Korea
9.4.4.1 South Korea Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
9.4.4.2 South Korea Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
9.4.4.3 South Korea Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)
9.5 Latin America
9.5.1 Latin America Crispr And Cas Genes Market Estimates And Forecast, 2016 - 2027 (USD Million)
9.5.2 Brazil
9.5.2.1 Brazil Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
9.5.2.2 Brazil Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
9.5.2.3 Brazil Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)
9.5.3 Mexico
9.5.3.1 Mexico Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
9.5.3.2 Mexico Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
9.5.3.3 Mexico Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)
9.6 Middle East & Africa (Mea)
9.6.1 Mea Crispr And Cas Genes Market Estimates And Forecast, 2016 - 2027 (USD Million)
9.6.2 South Africa
9.6.2.1 South Africa Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
9.6.2.2 South Africa Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
9.6.2.3 South Africa Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)
9.6.3 Saudi Arabia
9.6.3.1 Saudi Arabia Crispr And Cas Genes Market Estimates And Forecast, By Product & Service, 2016 - 2027 (USD Million)
9.6.3.2 Saudi Arabia Crispr And Cas Genes Market Estimates And Forecast, By Application, 2016 - 2027 (USD Million)
9.6.3.3 Saudi Arabia Crispr And Cas Genes Market Estimates And Forecast, By End - Use, 2016 - 2027 (USD Million)

Chapter 10 Company Profiles
10.1 Top Crispr Innovators And Their Research Focus
10.2 Strategy Framework
10.3 Market Participant Categorization
10.4 Company Profiles
10.4.1 Astrazeneca
10.4.1.1 Company Overview
10.4.1.2 Financial Performance
10.4.1.3 Product Benchmarking
10.4.1.4 Strategic Initiatives
10.4.2 Addgene
10.4.2.1 Company Overview
10.4.2.2 Financial Performance
10.4.2.3 Product Benchmarking
10.4.3 Caribou Biosciences, Inc.
10.4.3.1 Company Overview
10.4.3.2 Financial Performance
10.4.3.3 Product Benchmarking
10.4.3.4 Strategic Initiatives
10.4.4 Cellectis
10.4.4.1 Company Overview
10.4.4.2 Calyxt, Inc.
10.4.4.2.1 Company Overview
10.4.4.3 Financial Performance
10.4.4.3.1 Financial Performance (Calyxt, Inc.)
10.4.4.4 Product Benchmarking
10.4.4.5 Strategic Initiatives
10.4.5 Crispr Therapeutics
10.4.5.1 Company Overview
10.4.5.2 Financial Performance
10.4.5.3 Product Benchmarking
10.4.5.4 Strategic Initiatives
10.4.6 Editas Medicine, Inc.
10.4.6.1 Company Overview
10.4.6.2 Financial Performance
10.4.6.3 Product Benchmarking
10.4.6.4 Strategic Initiatives
10.4.7 Egenesis
10.4.7.1 Company Overview
10.4.7.2 Financial Performance
10.4.7.3 Product Benchmarking
10.4.7.4 Strategic Initiatives
10.4.8 F. Hoffmann - La Roche Ltd.
10.4.8.1 Company Overview
10.4.8.2 Mirus Bio Llc
10.4.8.2.1 Company Overview
10.4.8.3 Financial Performance
10.4.8.3.1 Financial Performance (Mirus Bio Llc)
10.4.8.4 Product Benchmarking
10.4.9 Horizon Discovery Group Plc
10.4.9.1 Company Overview
10.4.9.2 Dharmacon, Inc.
10.4.9.2.1 Company Overview
10.4.9.3 Financial Performance
10.4.9.4 Product Benchmarking
10.4.9.5 Strategic Initiatives
10.4.10 Genscript
10.4.10.1 Company Overview
10.4.10.2 Financial Performance
10.4.10.3 Product Benchmarking
10.4.10.4 Strategic Initiatives
10.4.11 Danaher Corporation
10.4.11.1 Company Overview
10.4.11.2 Integrated Dna Technologies, Inc.
10.4.11.2.1 Company Overview
10.4.11.3 Financial Performance
10.4.11.3.1 Financial Performance (Integrated Dna Technologies, Inc.)
10.4.11.4 Product Benchmarking
10.4.11.5 Strategic Initiatives
10.4.12 Intellia Therapeutics, Inc.
10.4.12.1 Company Overview
10.4.12.2 Financial Performance
10.4.12.3 Product Benchmarking
10.4.12.4 Strategic Initiatives
10.4.13 Lonza
10.4.13.1 Company Overview
10.4.13.2 Financial Performance
10.4.13.3 Product Benchmarking
10.4.13.4 Strategic Initiatives
10.4.14 Merck Kgaa
10.4.14.1 Company Overview
10.4.14.2 Sigma - Aldrich Co. Llc
10.4.14.2.1 Company Overview
10.4.14.3 Financial Performance
10.4.14.4 Product Benchmarking
10.4.14.5 Strategic Initiatives
10.4.15 New England Biolabs
10.4.15.1 Company Overview
10.4.15.2 Financial Performance
10.4.15.3 Product Benchmarking
10.4.15.4 Strategic Initiatives
10.4.16 Takara Bio, Inc.
10.4.16.1 Company Overview
10.4.16.2 Financial Performance
10.4.16.3 Product Benchmarking
10.4.16.4 Strategic Initiatives
10.4.17 Thermo Fisher Scientific, Inc.
10.4.17.1 Company Overview
10.4.17.2 Financial Performance
10.4.17.3 Product Benchmarking
10.4.17.4 Strategic Initiatives
10.4.18 Synthego
10.4.18.1 Company Overview
10.4.18.2 Financial Performance
10.4.18.3 Product Benchmarking
10.4.18.4 Strategic Initiatives
10.4.19 Mammoth Biosciences
10.4.19.1 Company Overview
10.4.19.2 Financial Performance
10.4.19.3 Product Benchmarking
10.4.19.4 Strategic Initiatives
10.4.20 Inscripta, Inc.
10.4.20.1 Company Overview
10.4.20.2 Financial Performance
10.4.20.3 Product Benchmarking
10.4.20.4 Strategic Initiatives
10.4.21 Cibus
10.4.21.1 Company Overview
10.4.21.2 Financial Performance
10.4.21.3 Product Benchmarking
10.4.21.4 Strategic Initiatives
10.4.22 Beam Therapeutics
10.4.22.1 Company Overview
10.4.22.2 Financial Performance
10.4.22.3 Product Benchmarking
10.4.22.4 Strategic Initiatives
10.4.23 Plantedit
10.4.23.1 Company Overview
10.4.23.2 Product Benchmarking
10.4.23.3 Strategic Initiatives
10.4.24 Vertex Pharmaceuticals Incorporated
10.4.24.1 Company Overview
10.4.24.2 Financial Performance
10.4.24.3 Product Benchmarking
10.4.24.4 Strategic Initiatives
10.4.25 Hera Biolabs
10.4.25.1 Company Overview
10.4.25.2 Product Benchmarking
10.4.25.3 Strategic Initiatives
10.4.26 Origene Technologies, Inc.
10.4.26.1 Company Overview
10.4.26.2 Financial Performance
10.4.26.3 Product Benchmarking
10.4.26.4 Strategic Initiatives
10.4.27 Recombinetics, Inc.
10.4.27.1 Company Overview
10.4.27.2 Financial Performance
10.4.27.3 Product Benchmarking
10.4.27.4 Strategic Initiatives



Note: Product cover images may vary from those shown
  • Astrazeneca
  • Addgene
  • Caribou Biosciences, Inc.
  • Cellectis
  • Crispr Therapeutics
  • Editas Medicine, Inc.
  • Egenesis
  • F. Hoffmann - La Roche Ltd.
  • Horizon Discovery Group Plc
  • Genscript
  • Danaher Corporation
  • Intellia Therapeutics, Inc.
  • Lonza
  • Merck Kgaa
  • New England Biolabs
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
  • Synthego
  • Mammoth Biosciences
  • Inscripta, Inc.
  • Cibus
  • Beam Therapeutics
  • Plantedit
  • Vertex Pharmaceuticals Incorporated
  • Hera Biolabs
  • Origene Technologies, Inc.
  • Recombinetics, Inc.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll